<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8" />
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0, user-scalable=no" />
        <title>Full STD Tx Guidelines</title>
        <link href="../jquery-mobile/jquery.mobile.theme-1.3.1.min.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.f.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.j.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/custom_arrow.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.structure-1.3.1.min.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/full.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/recreated_tables.css" rel="stylesheet" type="text/css"/>
        <script src="../jquery-mobile/jquery-1.9.1.min.js" type="text/javascript"></script>
        <script src="../../jquery-customization.js" type="text/javascript"></script>
        <script src="../jquery-mobile/jquery.mobile-1.3.1.min.js" type="text/javascript"></script>
        <script src="../../cordova-2.7.0.js" type="text/javascript" charset="utf-8"></script>
        <script src="../assets/js/metrics.js" type="text/javascript" charset="utf-8"></script>
    </head>
    <body onload="onLoad()">
        <!-- Start of page -->
        <div data-role="page" id="g417" data-theme="d">
            <div data-role="header" data-id="guidelines-header" data-theme="j" data-position="fixed">
                <a href="lv-409.html" data-role="button" data-iconshadow="false" data-corners="false" data-theme="reset" data-transition="fade" class="back_button" role="button" aria-label="back"></a>
                <h1>Full STD Tx Guidelines</h1>
	            <a href="../menu.html"  rel="external" data-role="button" data-theme="reset" data-transition="fade" data-iconshadow="false" data-corners="false" class="menu_button ui-btn-right" role="button" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-0.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-409.html" >References</a><span class="carrot"> > </span>References 351-400
            </div>
            </br><h2 id="sigil_toc_id_417">
 References 351-400
</h2>
<p>
 351. Joesoef MR, Hillier SL, Wiknjosastro G, et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Am J Obstet Gynecol 1995;173:1527&ndash;31.
</p>
<p>
 352. Jamieson DJ, Duerr A, Klein RS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol 2001;98:656&ndash;63.
</p>
<p>
 353. Van Der PB, Williams JA, Orr DP, et al. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis 2005;192:2039&ndash;44.
</p>
<p>
 354. Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001&ndash;2004. Clin Infect Dis 2007;45:1319&ndash;26.
</p>
<p>
 355. Lara-Torre E, Pinkerton JS. Accuracy of detection of Trichomonas vaginalis organisms on a liquid-based papanicolaou smear. Am J Obstet Gynecol 2003;188:354&ndash;6.
</p>
<p>
 356. Van Der PB, Kraft CS, Williams JA. Use of an adaptation of a commercially&nbsp;available PCR assay aimed at diagnosis of chlamydia and gonorrhea to detect Trichomonas vaginalis in urogenital specimens. J Clin Microbiol 2006;44:366&ndash;73.
</p>
<p>
 357. Hardick A, Hardick J, Wood BJ, et al. Comparison between the Gen-Probe transcription-mediated amplification Trichomonas vaginalis research assay and real-time PCR for Trichomonas vaginalis detection using a Roche LightCycler instrument with female self-obtained vaginal swab samples and male urine samples. J Clin Microbiol 2006;44:4197&ndash;9.
</p>
<p>
 358. Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares&nbsp;favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis 2007;45:194&ndash;8.
</p>
<p>
 359. Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis&nbsp;of trichomoniasis in men and women. Am J Obstet Gynecol 2009;200:188&ndash;97.
</p>
<p>
 360. Francis SC, Kent CK, Klausner JD, et al. Prevalence of rectal Trichomonas vaginalis and Mycoplasma genitalium in male patients at the San Francisco STD clinic, 2005&ndash;2006. Sex Transm Dis 2008;35:797&ndash;800.
</p>
<p>
 361. Forna F, Gulmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003;(2):CD000218.
</p>
<p>
 362. Schmid G, Narcisi E, Mosure D, et al. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med 2001;46:545&ndash;9.
</p>
<p>
 363. Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother 2006;50:4209&ndash;10.
</p>
<p>
 364. Pearlman MD, Yashar C, Ernst S, et al. An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse reaction to metronidazole. Am J Obstet Gynecol 1996;174:934&ndash;6.
</p>
<p>
 365. Kurohara ML, Kwong FK, Lebherz TB, et al. Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol 1991;88:279&ndash;80.
</p>
<p>
 366. Helms DJ, Mosure DJ, Secor WE, et al. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008;198:370&ndash;7.
</p>
<p>
 367. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001;345:487&ndash;93.
</p>
<p>
 368. Kigozi GG, Brahmbhatt H, Wabwire-Mangen F, et al. Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis&nbsp;of a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2003;189:1398&ndash;1400.
</p>
<p>
 369. Caro-Paton T, Carvajal A, Martin dD, I, et al. Is metronidazole teratogenic?&nbsp;A meta-analysis. Br J Clin Pharmacol 1997;44:179&ndash;82.
</p>
<p>
 370. Van Der PB, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis 2008;197:548&ndash;54.
</p>
<p>
 371. Moodley P, Wilkinson D, Connolly C, et al. Influence of HIV-1 coinfection on effective management of abnormal vaginal discharge. Sex Transm Dis 2003;30:1&ndash;5.
</p>
<p>
 372. Moodley P, Wilkinson D, Connolly C, et al. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis 2002;34:519&ndash;22.
</p>
<p>
 373. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007;195:698&ndash;702.
</p>
<p>
 374. Kissinger P, Secor WE, Leichliter JS, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis 2008;46:994&ndash;9.
</p>
<p>
 375. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 2009;36:11&ndash;6.
</p>
<p>
 376. Tuomala RE, O&lsquo;Driscoll PT, Bremer JW, et al. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis 2003;187:375&ndash;84.
</p>
<p>
 377. Wang CC, Mcclelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001;183:1017&ndash;22.
</p>
<p>
 378. Niccolai LM, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000;27:284&ndash;8.
</p>
<p>
 379. Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010;55:565-71.
</p>
<p>
 380. Sobel JD, Chaim W, Nagappan V, et al. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003;189:1297&ndash;1300.
</p>
<p>
 381. Vazquez JA, Peng G, Sobel JD, et al. Evolution of antifungal susceptibility&nbsp;among Candida species isolates recovered from human immunodeficiency&nbsp;virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis 2001;33:1069&ndash;75.
</p>
<p>
 382. Wiesenfeld HC, Sweet RL, Ness RB, et al. Comparison of acute and subclinical&nbsp;pelvic inflammatory disease. Sex Transm Dis 2005;32:400&ndash;5.
</p>
<p>
 383. Ness RB, Kip KE, Hillier SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol 2005;162:585&ndash;90.
</p>
<p>
 384. Cohen CR, Mugo NR, Astete SG, et al. Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis. Sex Transm Infect 2005;81:463&ndash;66.
</p>
<p>
 385. Jurstrand M, Jensen JS, Magnuson A, et al. A serological study of the role of Mycoplasma genitalium in pelvic inflammatory disease and ectopic pregnancy. Sex Transm Infect 2007;83:319&ndash;23.
</p>
<p>
 386. Short VL, Totten PA, Ness RB, et al. Clinical presentation of Mycoplasma genitalium infection versus Neisseria gonorrhoeae infection&nbsp;among women with pelvic inflammatory disease. Clin Infect Dis 2009;48:41&ndash;7.
</p>
<p>
 387. Peipert JF, Ness RB, Blume J, et al. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. Am J Obstet Gynecol 2001;184:856&ndash;63.
</p>
<p>
 388. Gaitan H, Angel E, Diaz R, et al. Accuracy of five different diagnostic techniques in mild-to-moderate pelvic inflammatory disease. Infect Dis Obstet Gynecol 2002;10:171&ndash;80.
</p>
<p>
 389. Haggerty CL, Ness RB, Amortegui A, et al. Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol 2003;188:141&ndash;8.
</p>
<p>
 390. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929&ndash;37.
</p>
<p>
 391. Ness RB, Hillier SL, Kip KE ea. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 2004;44 (Supp 3):S111&ndash;22.
</p>
<p>
 392. Smith KJ, Ness RB, Wiesenfeld HC, et al. Cost-effectiveness of alternative&nbsp;outpatient pelvic inflammatory disease treatment strategies. Sex Transm Dis 2007;34:960&ndash;6.
</p>
<p>
 393. Walker CK, Wiesenfeld H. Antibiotic Therapy for Acute Pelvic Inflammatory Disease: The 2006 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 2007;28(Supp 1):S29&ndash;S36.
</p>
<p>
 394. McGregor JA, Crombleholme WR, Newton E, et al. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 1994;83:998&ndash;1004.
</p>
<p>
 395. Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin&nbsp;as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003;31:45&ndash;54.
</p>
<p>
 396. Savaris RF, Teixeira LM, Torres TG, et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized&nbsp;controlled trial. Obstet Gynecol 2007;110:53&ndash;60.
</p>
<p>
 397. Bukusi EA, Cohen CR, Stevens CE, et al. Effects of human immunodeficiency&nbsp;virus 1 infection on microbial origins of pelvic inflammatory disease and on efficacy of ambulatory oral therapy. Am J Obstet Gynecol 1999;181:1374&ndash;81.
</p>
<p>
 398. Irwin KL, Moorman AC, O&lsquo;Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol 2000;95:525&ndash;34.
</p>
<p>
 399. Mugo NR, Kiehlbauch JA, Nguti R, et al. Effect of human immunodeficiency&nbsp;virus-1 infection on treatment outcome of acute salpingitis. Obstet Gynecol 2006;107:807&ndash;12.
</p>
<p>
 400. Viberga I, Odlind V, Lazdane G, et al. Microbiology profile in women with pelvic inflammatory disease in relation to IUD use. Infect Dis Obstet Gynecol 2005;13:183&ndash;90.
 <br/>
</p>

            </div>
            <script type="text/javascript">
                $('#g417').on('pageshow', function (event, ui) {
                    document.addEventListener("deviceready", function(){
                        trackFullGuidelinesPageView('417');
                                                },true);
                });
            </script>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

